Ginsenoside Rh2 differentially Mediates microRNA Expression to Prevent Chemoresistance of Breast Cancer
Open Access
- 4 March 2015
- journal article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (3), 1105-1109
- https://doi.org/10.7314/apjcp.2015.16.3.1105
Abstract
Chemoresistance is the most common cause of chemotherapy failure during breast cancer (BCA) treatment. It is generally known that the mechanisms of chemoresistance in tumors involve multiple genes and multiple signaling pathways,; if appropriate drugs are used to regulate the mechanisms at the gene level, it should be possible to effectively reverse chemoresistance in BCA cells. It has been confirmed that chemoresistance in BCA cells could be reversed by ginsenoside Rh2 (G-Rh2). Preliminary studies of our group identified some drug- resistance specific miRNA. Accordingly, we proposed that G-Rh2 could mediate drug-resistance specific miRNA and corresponding target genes through the gene regulatory network; this could cut off the drug-resistance process in tumors and enhance treatment effects. G-Rh2 and breast cancer cells were used in our study. Through pharmaceutical interventions, we could explore how G-Rh2 could inhibit chemotherapy resistance in BCA, and analyze its impact on related miRNA and target genes. Finally, we will reveal the anti-resistance molecular mechanisms of G-Rh2 from a different angle in miRNA-mediated chemoresistance signals among cells.Keywords
This publication has 17 references indexed in Scilit:
- Outcomes Based on Risk Assessment of Anastomotic Leakage after Rectal Cancer SurgeryAsian Pacific Journal of Cancer Prevention, 2014
- Restoration of p53/miR‐34a regulatory axis decreases survival advantage and ensures Bax‐dependent apoptosis of non‐small cell lung carcinoma cellsFEBS Letters, 2014
- miR-511 induces the apoptosis of radioresistant lung adenocarcinoma cells by triggering BAXOncology Reports, 2014
- MicroRNA-15b contributes to ginsenoside-Rg1-induced angiogenesis through increased expression of VEGFR-2Biochemical Pharmacology, 2013
- Phase II Trial of Loubo®(Lobaplatin) and Pemetrexed for Patients with Metastatic Breast Cancer not Responding to Anthracycline or TaxanesAsian Pacific Journal of Cancer Prevention, 2013
- Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cellsOncology Reports, 2012
- MicroRNA-34a Modulates Chemosensitivity of Breast Cancer Cells to Adriamycin by Targeting Notch1Archives of Medical Research, 2012
- Secreted microRNAs: a new form of intercellular communicationTrends in Cell Biology, 2012
- MicroRNA-mediated drug resistance in breast cancerClinical Epigenetics, 2011
- Ginsenoside Rh2 induces Bcl‐2 family proteins‐mediated apoptosis in vitro and in xenografts in vivo modelsJournal of Cellular Biochemistry, 2010